Get the Stockscreener App
9.10
3.91%
-0.37
After Hours:
9.10
Vir Biotechnology Inc Stock (VIR) Latest News
Vir Biotechnology CEO sells $152,407 in stock By Investing.com - Investing.com Canada
Vir Biotechnology's SVP sells shares worth $14,766 By Investing.com - Investing.com Australia
Vir Biotechnology EVP vanina de Verneuil sells $48,590 in shares By Investing.com - Investing.com Australia
Vir Biotechnology CEO sells $152,407 in stock - Investing.com India
Vir Biotechnology EVP sells shares worth $133,935 - Investing.com
(VIR) Trading Advice - Stock Traders Daily
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference - BioSpace
Vir Biotechnology director George Scangos sells $107,575 in stock By Investing.com - Investing.com Nigeria
Vir Biotechnology director George Scangos sells $107,575 in stock - Investing.com
Will Vir Biotechnology Reveal New Strategic Initiatives? Key Conference Appearance Ahead - StockTitan
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Empowered Funds LLC - MarketBeat
Brent Sabatini Sells 1,562 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock - MarketBeat
Vir Biotechnology SVP sells shares for $14,291 - MSN
Xencor, Inc. Enters License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat Covid-19 with Vir Biotechnology - Marketscreener.com
Vir Biotechnology (NASDAQ:VIR) Shares Down 4.8%Here's Why - MarketBeat
Vir Biotechnology SVP sells shares for $14,291 By Investing.com - Investing.com Nigeria
Vir Biotechnology Officer Sells Shares to Cover Tax Obligations - TradingView
abrdn plc Buys Shares of 363,161 Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Business Wire
Vir Biotechnology Sets Stage for Major Corporate Strategy Reveal with Q4 Earnings - StockTitan
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
(VIR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Vir Biotechnology price target raised to $14 from $10 at JPMorgan - MSN
FY2029 EPS Estimate for Vir Biotechnology Lowered by Analyst - MarketBeat
After a year of 7.8% returns, Vir Biotechnology, Inc.'s (NASDAQ:VIR) share price drop last week may have less of an impact on institutional investors - Simply Wall St
NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer - BioSpace
HC Wainwright Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Short Interest Update - MarketBeat
Vir Biotechnology appoints new Chief Technical Officer By Investing.com - Investing.com Australia
Vir Biotechnology Inc. (VIR) Stock Overview and Recent Developments – Market - HPBL
Vir Biotechnology Shares Surge After Opening Higher: A Market Overview – Market - HPBL
Vir Biotechnology, Inc. Announces Executive Changes -January 30, 2025 at 07:51 am EST - Marketscreener.com
Vir Biotechnology appoints new Chief Technical Officer - Investing.com
Vir Biotechnology Announces Leadership Change in 2025 - TipRanks
Vir Biotechnology Inc. (VIR) Announces CTO Departure - StreetInsider.com
Trading (VIR) With Integrated Risk Controls - Stock Traders Daily
Vir Biotechnology Phase 1 Data on Dual-Masked T-Cell Engagers (TCEs) – Market - HPBL
Vir Biotechnology (NASDAQ:VIR) Shares Down 3.8%Should You Sell? - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Shares Up 6.3%What's Next? - MarketBeat
Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now - Insider Monkey
Hepatitis B Virus Infection Clinical and Non-Clinical Studies, - openPR
Vir, Sana gain new modality POC: BioCentury’s Clinical Report - BioCentury
JP Morgan Week 2025 – Marianne De Backer - pharmaphorum
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):